Elevara
London, GB · 3 known investors
Elevara Medicines is a clinical-stage biotech developing ELV001, a first-in-class once-daily oral CDK4/6 inhibitor that targets fibroblast-like synoviocytes as an add-on therapy for rheumatoid arthritis and other chronic inflammatory diseases. Its drug is designed to combine with existing DMARDs for patients who have an inadequate response to standard treatments like methotrexate and TNF inhibitors.
BiotechHealthtechMedical Devices
Founders & leadership
ET
Emma TinsleyFounder & former CEO (now Non-Executive Director)
MZ
Mai-Britt ZoccaCEO